ISSN 2168-622X, 2168-6238
85 papers in the library · 7,976 citations · publishing 2013-2026
JAMA Psychiatry March 29, 2023 Sarah Mcnamee, Neşe Devenot, Meaghan Buisson 167 citations
This Viewpoint discusses serious adverse events linked to interactions between therapists and patients in trials of psychedelic-assisted therapy.
JAMA Psychiatry March 8, 2023 Philip R. Corlett, Sonia Bansal, James M. Gold 1 citation
Importance: Distinguishing delusions and hallucinations from unusual beliefs and experiences has proven challenging. Observations: The advent of neural network and generative modeling approaches to big data offers a challenge and an opportunity; healthy individuals with unusual beliefs and experiences who are not ill may raise false alarms and serve as adversarial examples to such networks....
JAMA Psychiatry 2023 Brian D Kiluk, Bethea A Kleykamp, Sandra D Comer et al. 22 citations
Novel treatments for opioid use disorder (OUD) are needed to address both the ongoing opioid epidemic and long-standing barriers to existing OUD treatments that target the endogenous μ-opioid receptor (MOR) system. The goal of this review is to highlight unique clinical trial design considerations for the study of emerging treatments for OUD that address targets beyond the MOR system. In...
JAMA Psychiatry January 1, 2023 Elizabeth A Hoge, Eric Bui, Mihriye Mete et al.
Anxiety disorders are common, highly distressing, and impairing conditions. Effective treatments exist, but many patients do not access or respond to them. Mindfulness-based interventions, such as mindfulness-based stress reduction (MBSR) are popular and can decrease anxiety, but it is unknown how they compare to standard first-line treatments. To determine whether MBSR is noninferior to...
JAMA Psychiatry December 7, 2022 Joshua S. Siegel, James E. Daily, Demetrius Perry et al. 168 citations
Importance Psychedelic drugs are becoming accessible in the US through a patchwork of state legislative reforms. This shift necessitates consensus on treatment models, education and guidance for health care professionals, and planning for implementation and regulation. Objective To assess trends in psychedelics legislative reform and legalization in the US to provide guidance to health care...
JAMA Psychiatry October 19, 2022 T. Rhee, S. Shim, B. Forester et al. 139 citations
Importance Whether ketamine is as effective as electroconvulsive therapy (ECT) among patients with major depressive episode remains unknown. Objective To systematically review and meta-analyze data about clinical efficacy and safety for ketamine and ECT in patients with major depressive episode. Data Sources PubMed, MEDLINE, Cochrane Library, and Embase were systematically searched using...
JAMA Psychiatry October 1, 2022 David B. Yaden, James B. Potash, Roland R. Griffiths 153 citations
This Viewpoint presents impediments to the clinical application of psychedelics created by extreme shifts in public perception while advocating further study and encouraging the dispute of claims not supported by available evidence.
JAMA Psychiatry September 28, 2022 Hugo Bottemanne, Orphée Morlaàs, Anne Claret et al. 59 citations
Key Points Question What are the effects of ketamine on belief updating in patients with treatment-resistant depression (TRD)? Findings This case-control study in patients with TRD showed that belief updating became more optimistically biased as soon as 4 hours after a first ketamine infusion. This early cognitive effect of ketamine was formalized by stronger asymmetrical reinforcement learning...
JAMA Psychiatry August 24, 2022 Michael P. Bogenschutz, Stephen Ross, Snehal Bhatt et al. 668 citations
Importance Although classic psychedelic medications have shown promise in the treatment of alcohol use disorder (AUD), the efficacy of psilocybin remains unknown. Objective To evaluate whether 2 administrations of high-dose psilocybin improve the percentage of heavy drinking days in patients with AUD undergoing psychotherapy relative to outcomes observed with active placebo medication and...
JAMA Psychiatry May 11, 2022 Sina Nikayin, Taeho Greg Rhee, Maria Elena Cunningham et al. 43 citations
This comparative analysis examines the trajectory of depression severity among patients treated with intravenous ketamine or intranasal esketamine in a clinical setting.
JAMA Psychiatry April 27, 2022 Mazdak M. Bradberry, Natalie Gukasyan, Charles L. Raison 20 citations
Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA...
JAMA Psychiatry March 1, 2022 Thomas D Marcotte, Anya Umlauf, David J Grelotti et al.
Expanding cannabis medicalization and legalization increases the urgency to understand the factors associated with acute driving impairment. To determine, in a large sample of regular cannabis users, the magnitude and time course of driving impairment produced by smoked cannabis of different Δ9-tetrahydrocannabinol (THC) content, the effects of use history, and concordance between perceived...
JAMA Psychiatry October 1, 2021 Philippe R. Goldin, Matthew D Thurston, Santiago Allende et al.
Cognitive behavioral group therapy (CBGT) and mindfulness-based stress reduction (MBSR) are thought to help patients with social anxiety disorder (SAD) via distinct emotion-regulation mechanisms. However, no study has compared the effects of CBGT and MBSR on brain and negative emotion indicators of cognitive reappraisal and acceptance in patients with SAD. To investigate the effects of CBGT and...
JAMA Psychiatry August 1, 2021 James C. Harris 4 citations
Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue
JAMA Psychiatry May 1, 2021 David B. Yaden, Mary E. Yaden, Roland R. Griffiths 102 citations
Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA...
JAMA Psychiatry February 10, 2021 Alan K. Davis, Roland R. Griffiths 3 citations
Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA...
JAMA Psychiatry February 1, 2021 David Nutt, Robin Carhart-Harris 233 citations
Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA...
JAMA Psychiatry November 4, 2020 Mary P Cosimano, Alan K. Davis, Frederick S. Barrett et al. 1,269 citations
Importance: Major depressive disorder (MDD) is a substantial public health burden, but current treatments have limited effectiveness and adherence. Recent evidence suggests that 1 or 2 administrations of psilocybin with psychological support produces antidepressant effects in patients with cancer and in those with treatment-resistant depression. Objective: To investigate the effect of...
JAMA Psychiatry November 4, 2020 Charles F. Reynolds 5 citations
Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA...
JAMA Psychiatry April 8, 2020 R. Murray, W. Hall
There is a worldwide trend toward liberalizing cannabis policy and commercializing its sale. Uruguay legalized recreational cannabis in 2013, as did Canada in 2018, as well as 10 US states.1 Other countries have decriminalized the drug. In Holland, cannabis can be bought in designated cafes, and in Portugal, the police refer those who regularly use cannabis for counseling. Psychiatrists have...
JAMA Psychiatry January 29, 2020 Z. Segal, Sona Dimidjian, A. Beck et al.
Importance Patients with residual depressive symptoms face a gap in care because few resources, to date, are available to manage the lingering effects of their illness. Objective To evaluate the effectiveness for treating residual depressive symptoms with Mindful Mood Balance (MMB), a web-based application that delivers mindfulness-based cognitive therapy, plus usual depression care compared...
JAMA Psychiatry June 26, 2019 Boris D. Heifets, Robert C. Malenka 28 citations
This Viewpoint discusses the potential therapeutic utility of methylenedioxy-methamphetamine and psilocybin and outlines mental health care infrastructures that would need to be put in place should these drugs be approved for treatment.
JAMA Psychiatry June 5, 2019 Ella Daly, Madhukar H. Trivedi, Adam Janik et al. 766 citations
Importance: Controlled studies have shown short-term efficacy of esketamine for treatment-resistant depression (TRD), but long-term effects remain to be established. Objective: To assess the efficacy of esketamine nasal spray plus an oral antidepressant compared with an oral antidepressant plus placebo nasal spray in delaying relapse of depressive symptoms in patients with TRD in stable...
JAMA Psychiatry March 1, 2019 Gihyun Yoon, Ismene L. Petrakis, John H. Krystal 152 citations
This study examines whether naltrexone pretreatment interferes with the antidepressant effects of ketamine.
JAMA Psychiatry October 22, 2018 Nicole R. Karcher, Deanna M Barch, Catherine H. Demers et al. 52 citations
Importance: Previous research indicates that cannabis use is associated with psychotic-like experiences (PLEs). However, it is unclear whether this association results from predispositional (ie, shared genetic) factors or individual-specific factors (eg, causal processes, such as cannabis use leading to PLEs). Objectives: To estimate genetic and environmental correlations between cannabis use...